top of page

Primary Lipid Disorders

Lipid Disorders

=  ILF Board Member Author(s)

Serum apolipoproteins and apolipoprotein
Coronary Artery Disease.jpg
soil food web2.jpg
statins and elderly.jpg
diabetes cvd guidelines.jpg
omega 3.jpg
proprotein convertase subtilisin kexin t
anti pcsk9 antibodies.jpg
Omega-3 Fatty Acid Based Nanolipid.jpg
pcsk9i july 2019.jpg
lipoprotein july 2019.jpg
lipid profile.jpg
Lipoprotein(a) 2.png
Coronary Artery Disease.jpg
icosapent ethyl.jpg
Chylomicronemia Syndrome.jpg
lipids 11jun19.jpg
ASCVD 11jun19.jpg
Apolipoprotein B.jpg
acute coronary syndrome.jpg
dietary lipids.jpg
cardiometabolic and brain.jpg
dietary lipids.jpg
2may19 493ss_thinkstock_rf_heart_anatomy
2may19 dyslipidemia.jpg
lipids 23apr19.jpg
23apr19 Atheroma Plaque Progression.jpg
3-D Strain Imaging of the Carotid Bifurc
dietary cholesterol.jpg
bile acid liver.jpg
Bempedoic Acid.jpg
ATP citrate lyase.jpg
bile acid liver.jpg
Fibroblast growth.png
pcsk9 and ldl.png
familial hypercholesterolemia pic.jpg
pcsk9 inhibitor.jpg
pcsk9i graphic.jpg
lipids in body.jpg
Vasorum Angiogenesis.jpg
Diabetic Retinopathy.jpg
ldl cholesterol.jpg
pcsk9 inhibitor.jpg

Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D.

The influence of statin monotherapy and statin-ezetimibe combined therapy on FoxP3 and IL 10 mRNA expression in patients with coronary artery disease.

Determination of four omega-3 polyunsaturated fatty acids by UPLC-MS/MS in plasma of

hyperlipidemic and normolipidemic subjects

Diversity and specificity of lipid patterns in basal soil food web resources

Statins and Elderly: From Clinical Trials to Daily Practice

Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction
of Cardiovascular Disease

Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and
Atherosclerotic Cardiovascular Disease

Omega-3 polyunsaturated fatty acids impinge on CD4+ T cell motility and adipose tissue
distribution via direct and lipid mediator-dependent effects

The patient journey with proprotein convertase subtilisin/kexin type 9 inhibitors in community practice

Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice

Omega-3 Fatty Acid Based Nanolipid Formulation of Atorvastatin for Treating Hyperlipidemia

Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes

Treatment with fibrates is associated with higher LAL activity in dyslipidemic patients

Inpatient statin use and stroke recurrence in patients with or without diabetes mellitus

Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight

apolipoprotein(a) phenotype

Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review

Lipoprotein(a): Current Evidence for a Physiologic Role and the Effects of Nutraceutical Strategies.

The Impact of Pre- and Post-Stroke Statin Use on Stroke Severity and Long-Term Outcomes:

A Population-Based Cohort Study.

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events:

Pooled analysis of alirocumab phase 3 trials.

Coronary Artery Disease Risk and Lipidomic Profiles Are Similar inHyperlipidemias With Family

History and Population-Ascertained Hyperlipidemias

Computationally Driven Structure Optimization, Synthesis, and Biological Evaluation of Imidazole-Based Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors

Non-Targeted LC-MS/MS Assay for Screening Over 100 Lipid Mediators from ARA, EPA, and

DHA in Biological Samples Based on Mass Spectral Fragmentations

Use of Guideline-Recommended Risk-Reduction Strategies Among Patients with Diabetes and Atherosclerotic Cardiovascular Disease: Insights from Getting to an Improved Understanding of

Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)

Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease

Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides:

The Randomized, Placebo-controlled ANCHOR Study

The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment

Association between Lipid Testing and Statin Adherence in the Veterans Affairs Health System

Current Trends in Non-HDL-Cholesterol and LDL-Cholesterol Levels in Adults with Atherosclerotic Cardiovascular Disease

Trends in Levels of Lipids and Apolipoprotein B in US Youths Aged 6 to 19 Years, 1999-2016

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD

Association between plasma lipid levels during acute coronary syndrome and long-term

malignancy risk. The ABC-4* study on heart disease.

A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in

9293 individuals

An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney

disease patients

The association of the PCSK9 rs562556 polymorphism with serum lipids level: a meta-analysis

Risk of cardiometabolic diseases among siblings of patients with bipolar disorder

Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen.

Role of dietary lipids in food allergy

Dissecting the membrane lipid binding properties and lipase activity of Mycobacterium tuberculosis LipY domains.

Primary care management of cardiovascular risk for people with severe mental illnesses: the Primrose research programme including cluster RCT

Development and application of a high throughput one-pot extraction protocol for quantitative LC-MS/MS analysis of phospholipids in serum and lipoprotein fractions in normolipidemic and dyslipidemic subjects

On the axial distribution of plaque stress: Influence of stenosis severity, lipid core stiffness, lipid core length and fibrous cap stiffness.

Persistent Dysfunction of Coronary Endothelial Vasomotor Responses is Related to Atheroma Plaque Progression in the Infarct-Related Coronary Artery of AMI Survivors

3-D Strain Imaging of the Carotid Bifurcation: Methods and in-Human Feasibility.

Plasma oxylipins respond in a linear dose-response manner with increased intake of EPA and DHA: results from a randomized controlled trial in healthy humans

Dietary cholesterol is essential to mast cell activation and associated obesity and diabetes in mice

Reexamining Recommendations for Treatment of Hypercholesterolemia in Older Adults

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study.

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study

Mendelian Randomization Study of ACLY and Cardiovascular Disease

Introduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic Properties

Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab

Commentary from Michael Shapiro, DO

Full Article


A New Personalized, Patient-Centric, and Cost-Conscious Guideline for Contemporary Cholesterol Management

New Cholesterol Guidelines Personalize Risk and Add Treatments

Association of cardiovascular events and lipoprotein particle size: Development of a risk score based on functional data analysis

Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

Lipid profile and genetic status in a familial hypercholesterolemia pediatric population: exploring the LDL/HDL ratio

Application of PCSK9 Inhibitors in Practice - Part 2: The Patient Experience

Cholesterol-Lowering Agents: PCSK9 Inhibitors Today and Tomorrow

Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Reduction in Vasa Vasorum Angiogenesis by Lp-PLA2 Selective Inhibitor Through The HIF-1α and VEGF Expression Under Dyslipidemic Conditions in Atherosclerosis Pathogenesis.

Achieving LDL‐C target levels less than 70 mg/dL may provide extra cardiovascular protection in high‐risk patients: exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients With Hypercholesterolemia and Diabetic Retinopathy Study

Compliance With Dyslipidemia Guidelines in Daily Practice: How Effective Is Cardiovascular Risk Prevention?

Effect of Evolocumab on Coronary Plaque Composition.

Berberrubine and its analog, hydroxypropyl‐berberrubine, regulate LDLR and PCSK9 expression via the ERK signal pathway to exert cholesterol‐lowering effects in human hepatoma HepG2 cells

The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk.

Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen on the surface of vascular endothelial and smooth muscle cells.

Use of Plasma Metabolomics to Analyze Phenotype-Genotype Relationships in Young
Hypercholesterolemic Females

Integrating epigenetic, genetic, and phenotypic data to uncover gene-region associations with triglycerides in the GOLDN study

Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan

A Meta-Analysis of the Effect of PCSK9-Monoclonal Antibodies on Circulating Lipoprotein (a) Levels.

Sex-specific relationship between visceral fat index and dyslipidemia in Chinese rural adults: The Henan Rural Cohort Study.

Safety and efficacy of Melissa officinalis (lemon balm) on ApoA-I, Apo B, lipid ratio and ICAM-1 in type 2 diabetes patients: A randomized, double-blinded clinical trial.

Assessment of Omega-3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale and Design of the STRENGTH Trial.

Effects of chelator lipids, paramagnetic metal ions and trehalose on liposomes by solid-state NMR

Role of lipoprotein (a) and LPA KIV2 repeat polymorphism in bicuspid aortic valve stenosis and calcification: a proof of concept study.

Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels

Lipid Profile and Long‐term Outcome in Premature Myocardial Infarction

Statement for Appropriate Clinical Use of PCSK9 Inhibitors

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.

Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management.

High Baseline Lipoprotein(a) Level as a Risk Factor for Coronary Artery Calcification Progression: Sub-analysis of a Prospective Multicenter Trial.

Full Article

Summary from R. Preston Mason, PhD

Slides from R. Preston Mason, PhD

Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry.

Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry

Identification of carotid lipid-rich necrotic core and calcification by 3D magnetization-prepared rapid acquisition gradient-echo imaging.

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia.

Bioactive lipids ALIAmides differentially modulate inflammatory responses of distinct subsets of primary human T lymphocytes.

Identification of six novel susceptibility loci for dyslipidemia using longitudinal exome-wide association studies in a Japanese population.

High density lipoprotein cholesterol and cancer: Marker or causative?

PCSK9: From Basic Science Discoveries to Clinical Trials

Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL

Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients

Residual Inflammatory Risk On Treatment with PCSK9 Inhibition and Statin Therapy.

Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes.

Optimization of lipid-assisted nanoparticle for disturbing neutrophils-related inflammation.

Novel enzymatic method for assaying Lp-PLA2 in serum.

Plasma fatty acid levels and gene expression related to lipid metabolism in peripheral blood mononuclear cells: a cross-sectional study in healthy subjects.

Role of sEH R287Q in LDLR expression, LDL binding to LDLR and LDL internalization in BEL-7402 cells.

Lipoprotein Lipase Is a Feature of Alternatively-Activated Microglia and May Facilitate Lipid Uptake in the CNS During Demyelination

Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER.

Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.

Lipid Lowering in Acute Coronary SyndromeIs Treatment Early Enough?

ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.

Relationship Between Lipoprotein Subfraction Cholesterol and Residual Risk for Cardiovascular Outcomes: A Post Hoc Analysis of the Aim-High Trial

PCSK-9 Inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer

Alirocumab in high-risk patients: Observations from the open-label expanded use program.

Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.

Slides from Matthew Budoff, MD

Summary from Matthew Budoff, MD

Relationship of Circulating miRNAs with Insulin Sensitivity and Associated Metabolic Risk Factors in Humans.

Efficacy of a telephone-based medical nutrition program on blood lipid and lipoprotein metabolism: Results of Our Healthy Heart.

Slides from W. Timothy Garvey, MD

Summary from W. Timothy Garvey, MD

Ezetimibe prescriptions in older Canadian adults after an acute myocardial infarction: a population-based cohort study.

Extracellular fungal polyol lipids: A new class of potential high value lipids.

Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies.

Associations between Lifestyle-Related Diseases and Transporters Involved in Intestinal Absorption and Biliary Excretion of Cholesterol.

Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease.

Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT.

A Novel Generalized Lipodystrophy-associated Progeroid Syndrome due to recurrent heterozygous LMNA p.T10I Mutation.

Perspective: interesterified triglycerides, the recent increase in deaths from heart disease, and elevated blood viscosity.

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.

bottom of page